Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial ...

Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

Vorasidenib significantly reduced tumor growth rates in IDH1/2-mutant grade 2 glioma, improving PFS and TTNI compared to ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

Che-Kai Tsao, MD, MS, system chief of Solid Tumor Oncology at Northwell Health Cancer Institute, discusses new approaches that could change the standard of care for metastatic hormone-sensitive ...

The FDA has granted fast track designation to zotiraciclib (TG02), an oral central nervous sytem-penetrant multikinase inhibitor, for treatment of patients with recurrent high-grade gliomas (rHGG) ...

DS-1594b showed on-target biological activity but failed to achieve protocol-defined responses, leading to early trial termination. Differentiation syndrome occurred in 29.4% of patients, prompting ...

Historically, there was no clear standard of care nor regulatory approvals for therapy for SMM prior to the AQUILA study. The ...

Sequential ICV and IV administration of CR7-GD2 CAR T-cell therapy showed improved tolerability over concurrent dosing in ...

The 2025 American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida, begins on December 6. This year, ...